Cytosorbents Co. (NASDAQ:CTSO) Short Interest Update

Cytosorbents Co. (NASDAQ:CTSO) was the recipient of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,370,000 shares, an increase of 5.4% from the November 15th total of 1,300,000 shares. Based on an average daily volume of 123,700 shares, the days-to-cover ratio is presently 11.1 days.

Cytosorbents Stock Performance

Shares of NASDAQ:CTSO opened at $1.01 on Monday. Cytosorbents has a one year low of $0.70 and a one year high of $2.15. The firm has a market cap of $55.23 million, a PE ratio of -2.81 and a beta of 0.57. The firm’s 50 day simple moving average is $0.98 and its 200-day simple moving average is $1.02. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Atomi Financial Group Inc. acquired a new stake in shares of Cytosorbents during the 3rd quarter valued at about $51,000. Geode Capital Management LLC boosted its stake in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares during the last quarter. CM Management LLC increased its position in Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Sargent Investment Group LLC raised its position in shares of Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after buying an additional 67,181 shares during the period. Institutional investors own 32.87% of the company’s stock.

Wall Street Analyst Weigh In

CTSO has been the topic of several recent research reports. StockNews.com started coverage on shares of Cytosorbents in a research note on Thursday. They issued a “hold” rating on the stock. HC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.